바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.69 No.6
Citation Share

Levofloxacin and Torsades de Pointes

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2010, v.69 no.6, pp.474-479









& (2010). Levofloxacin and Torsades de Pointes. Tuberculosis & Respiratory Diseases, 69(6), 474-479.
  • Downloaded
  • Viewed
PDF Download

Abstract

Torsades de pointes associated with a prolonged QT interval is a life-threatening arrhythmia, which may be induced by any of the following: drugs, electrolyte imbalances, severe bradycardia and intracranial hemorrhage. Torsades de pointes is characterized by beat-to-beat variations in the QRS complexes in any ECG leads with rates of 200∼250 per minute. Fluoroquinolones are widely used and well tolerated antibacterial agents. However, prolongation of the QT interval leads rarely to Torsades de pointes as a significant adverse effect. So, it should be used with caution in high-risk patients for developing Torsades de pointes. We report one case of 67-year old man with contact burns who experienced Torsades de pointes, which probably resulted from the use of levofloxacin, and no further episode occurred after its withdrawal.

keywords
levofloxacin, Torsades de Pointes, levofloxacin, Torsades de Pointes

Reference

1.

1. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41 Suppl 2:S144-57.

2.

2. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 1966;59:263-72.

3.

3. Roden DM. Drug-induced prolongation of the QT interval.N Engl J Med 2004;350:1013-22.

4.

4. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003;45:415-27.

5.

5. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW,Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983;2:806-17.

6.

6. Kim JH, Nam GB, Lim JM, Huh JW, Kim SY, Rhee KS,et al. A case of ofloxacin-induced torsades de pointes and abnormal ECG change mimicking acute myocardial infarction. Korean Circ J 2002;32:815-9.

7.

7. Kwon JW, Kang WC, Lee MH, Ahn SK, Kim SS. A case of hydroxyzine induced torsades de pointes. Korean Circ J 1998;28:1011-6.

8.

8. Park SJ, Kim KH, Kim JS, Ryu JC, Joo SB, Gwon HC,et al. Torsades de Pointes after combined treatment of terfenadine and ketoconazole. Korean J Med 1998;54:124-30.

9.

9. Letsas KP, Alexanian IP, Pappas LK, Kounas SP,Efremidis M, Sideris A, et al. QT interval prolongation and torsade de pointes associated with indapamide. Int J Cardiol 2006;112:373-4.

10.

10. Patel PD, Afshar H, Birnbaum Y. Levofloxacin-induced torsades de pointes. Tex Heart Inst J 2010;37:216-7.

11.

11. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin,and moxifloxacin. Pharmacotherapy 2001;21:1468-72.

12.

12. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB,Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73:292-303.

13.

13. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11:52-6.

14.

14. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001;59:122-6.

15.

15. Bazett HC. An analysis of the time-relations of electrocardiograms.Heart 1920;7:353-70.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy